Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi, Anahita, Dahlke, Christine, Krähling, Verena, Kupke, Alexandra, Okba, Nisreen M. A., Raadsen, Matthijs P., Heidepriem, Jasmin, Müller, Marcel A., Paris, Grigori, Lassen, Susan, Klüver, Michael, Volz, Asisa, Koch, Till, Ly, My L., Friedrich, Monika, Fux, Robert, Tscherne, Alina, Kalodimou, Georgia, Schmiedel, Stefan, Corman, Victor M., Hesterkamp, Thomas, Drosten, Christian, Loeffler, Felix F., Haagmans, Bart L., Sutter, Gerd, Becker, Stephan, Addo, Marylyn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295877/
https://www.ncbi.nlm.nih.gov/pubmed/35853863
http://dx.doi.org/10.1038/s41467-022-31557-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295877/
https://www.ncbi.nlm.nih.gov/pubmed/35853863
http://dx.doi.org/10.1038/s41467-022-31557-0

Ejemplares similares